Prime Medicine, Inc. (PRME)

NGM – Цена в реальном времени. Валюта: USD

3.30

+0.06 (1.85%)

При закрытии: May 12, 2026, 4:00 PM EDT

3.35

+0.05 (1.61%)

После закрытия: May 12, 2026, 7:34 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Prime Medicine, Inc. (PRME)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Prime Medicine, Inc. (PRME)

Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates

Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates

Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer

Prime Medicine, Inc. (PRME) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue Estimates

Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates

Prime Medicine to Participate in Upcoming Investor Conferences

Видео

No Data

Пресс-релизы

Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates

Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer

Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

Search stocks

Prime Medicine, Inc. (PRME)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Prime Medicine, Inc. (PRME)

Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates

Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates

Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer

Prime Medicine, Inc. (PRME) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue Estimates

Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates

Prime Medicine to Participate in Upcoming Investor Conferences

Видео

No Data

Пресс-релизы

Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates

Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer

Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease